These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Involuntary movement disorders. Still CN. Neurol Clin; 1984 Feb 17; 2(1):71-89. PubMed ID: 6239089 [Abstract] [Full Text] [Related]
45. [The treatment of headaches: an open randomized comparative therapeutic study (author's transl)]. Basquin S, Dubois M, Loukakis G, Maillot H, Mangenay L, Pacotte R, Questel R. Sem Hop; 1984 Feb 17; 55(15-16):806-9. PubMed ID: 227077 [Abstract] [Full Text] [Related]
51. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A. Clin Neuropharmacol; 2009 Feb 17; 32(4):189-92. PubMed ID: 19620848 [Abstract] [Full Text] [Related]
52. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. Maurel F, Lilliu H, Le Pen C. Rev Neurol (Paris); 2001 May 17; 157(5):507-14. PubMed ID: 11438770 [Abstract] [Full Text] [Related]
53. ["Induced detoxification treatment" of opiate dependent patients--a new therapy concept]. Loimer N, Presslich O, Lenz K, Pfersmann D, Schmid R, Fodor G, Aschauer G. Wien Klin Wochenschr; 1989 Jun 23; 101(13):451-4. PubMed ID: 2763565 [Abstract] [Full Text] [Related]
56. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai YM, Yu SC, Lin CC. J Clin Psychiatry; 2003 Nov 23; 64(11):1342-8. PubMed ID: 14658949 [Abstract] [Full Text] [Related]
57. [Alcohol withdrawal by tiapride. Respective contribution of the descriptive psychopathology and the quantitative psychopathology (author's transl)]. Bobon DP, Detaille J, Leunen A, Born-Leveque M. Acta Psychiatr Belg; 1980 Nov 23; 80(2):156-62. PubMed ID: 7468278 [Abstract] [Full Text] [Related]
58. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P. Clin Neuropharmacol; 2006 Nov 23; 29(3):112-25. PubMed ID: 16772809 [Abstract] [Full Text] [Related]